Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dual epigenetic therapy plus chemotherapy in peripheral T cell lymphoma with T follicular helper phenotype.

Med (New York, N.Y.) - 8 Nov 2024

Atallah-Yunes Suheil Albert, Wang Yucai

Abstract excerpt

The nonrandomized phase II study by Ding et al. explored the combination of azacitidine and chidamide with or without GemOx chemotherapy in relapsed/refractory peripheral T cell lymphoma and demonstrated that the dual epigenetic therapy is safe and efficacious, particularly in the angioimmunoblastic T cell lymphoma subset.1 Further investigation into adding chemotherapy is warranted, building on the promising...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminopyridines
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Azacitidine

Share to Benzamides

Share to Epigenesis, Genetic

Share to Lymphoma, T-Cell, Peripheral

Share to Phenotype

Source

Identifiers

PMID: 39520975
DOI: 10.1016/j.medj.2024.07.029

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dual epigenetic therapy plus chemotherapy in peripheral T cell lymphoma with T follicular helper phenotype.PMID 39520975Read ↗

Management of T-cell malignancies: Bench-to-bedside targeting of epigenetic biology.Semantic proximity Read ↗

Novel T Follicular Helper-like T-Cell Lymphoma Therapies: From Preclinical Evaluation to Clinical RealitySemantic proximity Read ↗

[Dual epigenetic therapy in TET2 gene positive extranodal peripheral T-cell lymphoma with follicular helper T-cell (TFH) phenotype: a case report and literature review].Semantic proximity Read ↗

TFH phenotype and response to tucidinostat in relapsed/refractory PTCL: analysis of patients from a phase IIb trial.Semantic proximity Read ↗

Follicular helper T-cell-related lymphomas.Semantic proximity Read ↗

Recent Progress in the Understanding of Angioimmunoblastic T-cell Lymphoma.Semantic proximity Read ↗

T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma.Semantic proximity Read ↗

Epigenetic focus on angioimmunoblastic T-cell lymphoma: pathogenesis and treatmentSemantic proximity Read ↗

Clinical and histological study of follicular helper T-cell lymphomas with indolent evolution.Semantic proximity Read ↗

Development of chidamide for peripheral T-cell lymphoma, the first orphan drug approved in ChinaSemantic proximity Read ↗

Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study.Semantic proximity Read ↗

Induction of p53-mediated apoptosis by azacitidine in patient-derived xenograft follicular helper T-cell lymphoma modelSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.